双期增强CT纹理分析参数预测肝细胞癌药物洗脱微球经动脉化疗栓塞疗效:与肝脏灌注CT的相关性
回顾性纳入28例患者56个肝细胞癌典型病灶,分析DEB-TACE前后动脉期和门静脉期CT纹理参数,并与肝脏灌注CT及mRECIST联合参考标准对比。动脉期部分纹理参数变化与灌注参数显著相关,偏度均匀性预测完全缓解敏感度90.0%、特异度45.8%,门静脉期异质性均匀性敏感度92.3%、特异度81.8%。
要点
- 动脉期纹理参数变化与灌注CT参数显著相关,门静脉期各组建模均无统计学显著相关。
- 门静脉期异质性均匀性预测完全缓解的敏感度92.3%、特异度81.8%,动脉期偏度均匀性敏感度90.0%、特异度45.8%。
- 纹理分析参数与灌注CT参数在TACE前后均存在显著相关性,部分参数对中期疗效有预测价值。
核心结论
- CT纹理分析参数与灌注CT参数在DEB-TACE前后均存在显著相关性,部分纹理参数对TACE中期疗效具有预测价值。
研究设计与样本
- 回顾性分析28例患者(27例男性,平均年龄67.2±10.4岁)共56个肝细胞癌典型肝脏病灶,分析DEB-TACE前后动脉期和门静脉期CT数据,两次检查平均间隔39.93±62.21天,TACE在首次增强CT后48小时内进行,以mRECIST联合肝脏灌注CT结果为参考标准。
诊断标准与关键数值
- 以mRECIST联合灌注CT为参考标准,完全缓解28.6%、部分缓解42.8%、稳定疾病28.6%;动脉期偏度均匀性预测完全缓解的截断值敏感度90.0%、特异度45.8%;门静脉期异质性均匀性预测完全缓解的截断值敏感度92.3%、特异度81.8%。
临床应用与阅片要点
- 纹理分析在动脉期和门静脉期均可作为灌注CT的补充手段评估DEB-TACE疗效,门静脉期异质性均匀性对完全缓解的预测特异度较高,动脉期偏度均匀性敏感度高但特异度有限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: This study aimed to evaluate the potential role of computed tomography texture analysis (CTTA) of arterial and portal-venous enhancement phase image data for prediction and accurate assessment of response of hepatocellular carcinoma undergoing drug-eluting bead transarterial chemoembolization (TACE) by comparison to liver perfusion CT (PCT).
MATERIALS AND METHODS: Twenty-eight patients (27 male; mean age 67.2 ± 10.4) with 56 hepatocellular carcinoma-typical liver lesions were included. Arterial and portal-venous phase CT data obtained before and after TACE with a mean time of 39.93 ± 62.21 days between examinations were analyzed. TACE was performed within 48 hours after first contrast-enhanced CT. CTTA software was a prototype. CTTA analysis was performed blinded (for results) by two observers separately. Combined results of modified Response Evaluation Criteria In Solid Tumors (mRECIST) and PCT of the liver were used as the standard of reference. Time to progression was additionally assessed for all patients. CTTA parameters included heterogeneity, intensity, average, deviation, skewness, and entropy of co-occurrence. Each parameter was compared to those of PCT (blood flow [BF], blood volume, arterial liver perfusion [ALP], portal-venous perfusion, and hepatic perfusion index) measured before and after TACE.
RESULTS: mRECIST + PCT yielded 28.6% complete response (CR), 42.8% partial response, and 28.6% stable disease. Significant correlations were registered in the arterial phase in CR between changes in mean heterogeneity and BF (P = .004, r = -0.815), blood volume (P = .002, r = -0.851), and ALP (P = .002, r = -0.851), respectively. In the partial response group, changes in mean heterogeneity correlated with changes in ALP (P = .003) and to a lesser degree with hepatic perfusion index (P = .027) in the arterial phase. In the stable disease group, BF correlated with entropy of nonuniformity (P = .010). In the portal-venous phase, no statistically significant correlations were registered in all groups. Receiver operating characteristic analysis of CTTA parameters yielded predictive cutoff values for CR in the arterial contrast-enhanced CT phase for uniformity of skewness (sensitivity: 90.0%; specificity: 45.8%), and in the portal-venous phase for uniformity of heterogeneity (sensitivity: 92.3%; specificity: 81.8%).
CONCLUSIONS: Significant correlations exist between CTTA parameters and those derived from PCT both in the pre- and the post-TACE settings, and some of them have predictive value for TACE midterm outcome.
引用
- Kloth C, Thaiss WM, Kärgel R, et al. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT. Acad Radiol. 2017. PMID: 28652049. doi:10.1016/j.acra.2017.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。